Homatropine
This article needs additional citations for verification. (October 2021) |
File:Homatropine.svg | |
Clinical data | |
---|---|
AHFS/Drugs.com | Monograph |
MedlinePlus | a601006 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C16H21NO3 |
Molar mass | 275.348 g·mol−1 |
3D model (JSmol) | |
| |
☒check (what is this?) (verify) |
Homatropine (Equipin, Isopto Homatropine) is an anticholinergic medication that is an antagonist at muscarinic acetylcholine receptors and thus the parasympathetic nervous system. It is used in eye drops as a cycloplegic (to temporarily paralyze accommodation), and as a mydriatic (to dilate the pupil). The related chemical compound homatropine methylbromide (methylhomatropine) is a different medication. Homatropine is less potent than atropine and has a shorter duration of action. It is available as the hydrobromide salt. Homatropine is also given as an atropine substitute,[1] given to reverse the muscarinic and CNS effects associated with indirect cholinomimetic (anti-AChase) administration. Homatropine hydrobromide is on the World Health Organization's List of Essential Medicines.[2] It is an antagonist of all five muscarinic acetylcholine receptors.[3]
Side effects
- Blurred vision
- Sensitivity to light
Contraindications
- Untreated glaucoma
- Myasthenia gravis
- Severe heart failure
- Thyrotoxicosis
References
- ↑ Scharer LL, Burhenne HJ (April 1964). "Megacolon associated with administration of an anticholinergic drug in a patient with ulcerative colitis". The American Journal of Digestive Diseases. 9 (4): 268–274. doi:10.1007/bf02232133. PMID 14142388. S2CID 19169565.
- ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ↑ Lavrador M, Cabral AC, Veríssimo MT, Fernandez-Llimos F, Figueiredo IV, Castel-Branco MM (January 2023). "A Universal Pharmacological-Based List of Drugs with Anticholinergic Activity". Pharmaceutics. 15 (1): 230. doi:10.3390/pharmaceutics15010230. PMC 9863833. PMID 36678858.
- Drugs with non-standard legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Drugs developed by Pfizer
- M1 receptor antagonists
- M2 receptor antagonists
- M3 receptor antagonists
- M4 receptor antagonists
- M5 receptor antagonists
- Ophthalmology drugs
- Tropanes